Evidence map›Paper›PMID 42527029›Full record

ArticleJournal for immunotherapy of cancer2026

Multi-omic characterization of 14q deletion in renal clear cell carcinoma identifies

Raven Vella, Emily L Hoskins, Ira D Miller, Julie W Reeser, Michele R Wing, Ankur Sheel, Eric Samorodnitsky, Sidney A Lenz, Katharine Collier, Mingjia Li and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Raven VellaDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.ORCID http://orcid.org/0000-0001-9630-3265
Emily L HoskinsLombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA.
Ira D MillerDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Julie W ReeserDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Michele R WingDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Ankur SheelDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Eric SamorodnitskyDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Sidney A LenzDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Katharine CollierDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Mingjia LiDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.ORCID http://orcid.org/0000-0002-3910-4179
Sayan M ChowdhuryDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Yuanquan YangDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.ORCID http://orcid.org/0000-0002-5209-9247
Anil ParwaniDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, USA.
Sameek RoychowdhuryDepartment of Internal Medicine, The Ohio State University, Columbus, Ohio, USA sameek.roychowdhury@osumc.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough chromosome 14q deletion (14q-) is present in up to 40% of clear cell renal cell carcinoma (ccRCC) cases, its immunologic and molecular impact remains unclear. Because

methodsWe collected data from 825 patients with ccRCC from publicly available sources, our own independent retrospective study, and the Oncology Research Information Exchange Network. These data include bulk RNA-sequencing (RNA-seq), single-cell RNA-seq (scRNA-seq), and whole exome sequencing (WES). We also include reverse phase protein array from DepMap cell lines (n=277). Next, we performed multiplex immunofluorescence for spatial analysis of immune cells on 23 patient slides with paired WES and ICB response. Finally, progression-free survival, 14q- status (assessed in bulk RNA-seq or whole exome sequencing), and kidney inflammatory marker

results14q- status is associated with increased NF-κB-target transcription and p65 phosphorylation. Tumor scRNA-seq revealed increased expression of

conclusionsThis is the first evidence that 14q- in ccRCC is associated with an antitumor inflammatory phenotype, possibly driven by aberrant NF-κB activation. Furthermore, 14q- with high

Indexed as

Carcinoma, Renal CellChromosome DeletionChromosomes, Human, Pair 14Immune Checkpoint InhibitorsImmunotherapyKidney NeoplasmsFemaleHumansMaleMiddle AgedMultiomicsImmune Checkpoint InhibitorsGenomeImmune Checkpoint InhibitorKidney Cancer

Identifiers

PMID42527029
PMCPMC13435989

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.